Democrats blast FDA labeling proposal
This article was originally published in The Gray Sheet
Eight Democratic representatives and senators urge FDA Jan. 23 not to finalize a proposed rule in which the agency seeks to "reaffirm" the limited authority drug and device firms have in altering labels without approval (1"The Gray Sheet" Jan. 21, 2008, p. 6). The lawmakers write that the proposal is "part of a pattern of actions in the Bush administration's final months to permanently insulate the drug and device industry from liability [for unsafe products].
You may also be interested in...
FDA is reiterating that a drug or device manufacturer may amend product labeling without prior agency approval only if it has "newly acquired" safety information about the product. In addition, the agency says companies may strengthen contraindications and warnings "only if there is sufficient evidence of a causal association with the drug, biologic, or device.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.